Improvement of the inactivated SARS-CoV-2 vaccine potency through formulation in alum/naloxone adjuvant; Robust T cell and anti-RBD IgG responses

OBJECTIVE(S): SARS-CoV-2, emerging as a major threat to public health, has to be controlled through vaccination. Naloxone (NLX), an opioid receptor antagonist, demonstrated its adjuvant activity for microbial vaccines. In this study, inactivated SARS-CoV-2 was developed in the Alum/NLX adjuvant to i...

Descripción completa

Detalles Bibliográficos
Autores principales: Haghighi, Melika, Khorasani, Akbar, Karimi, Pegah, Mahdavi, Mehdi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Mashhad University of Medical Sciences 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9282741/
https://www.ncbi.nlm.nih.gov/pubmed/35911642
http://dx.doi.org/10.22038/IJBMS.2022.63527.14015

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9282741/
https://www.ncbi.nlm.nih.gov/pubmed/35911642
http://dx.doi.org/10.22038/IJBMS.2022.63527.14015

Ejemplares similares